Consider Our Overview Before Taking a Position in NVS

Large-cap Healthcare company Novartis AG has logged a 1.1% change today on a trading volume of 966,820. The average volume for the stock is 2,327,698.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Based in Basel, Switzerland the company has 108,000 full time employees and a market cap of $195,741,007,872. Novartis AG currently offers its equity investors a dividend that yields 3.8% per year.

The company is now trading -9.68% away from its average analyst target price of $100.75 per share. The 4 analysts following the stock have set target prices ranging from $92 to $105, and on average give Novartis AG a rating of buy.

Over the last year, NVS shares have gone up 11.7%, which represents a difference of 23.1% when compared to the S&P 500. The stock's 52 week high is $94.26 per share whereas its 52 week low is $74.09. Based on Novartis AG's average gross margins growth of 1.1% over the last four years, its core business remains strong and the stock price may maintain this level of performance.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.